EXHIBIT 99.01 | ||
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ||
Press Release |
Notification of closing
Basingstoke, UK and Philadelphia, US – July 28, 2005 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced that the acquisition of Transkaryotic Therapies Inc. has successfully closed.
-ends-
For further information please contact: | ||||
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 | ||
Brian Piper (North America) | +1 484 595 8252 | |||
Media | Jessica Mann (Rest of the World) | +44 1256 894 280 | ||
Matthew Cabrey (North America) | +1 484 595 8248 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
Registered in England 2883758 Registered Office as above
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization, the impact of competitive products, including, but not limited to, the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire's ADHD franchise, government regulation and approval, including but not limited to Health Canada's suspension of ADDERALL XR® sales in Canada and the expected product approval dates of MTS (METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerative colitis), SPD480 (ulcerative colitis) and NRP104 (ADHD), including its scheduling classification by the Drug Enforcement Agency in the United States, Shire's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year to December 31, 2004.
Registered in England 2883758 Registered Office as above
EXHIBIT 99.02 | ||
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ||
Press Release | ||
Results of the Extraordinary General Meeting held on 27 July 2005
At the Extraordinary General Meeting of Shire Pharmaceuticals Group plc (“the Company”) held on 27 July 2005, the following resolution to approve the Company’s acquisition of Transkaryotic Therapies, Inc. (TKT) for approximately $1.6 billion in cash or $37.00 per ordinary share was passed on a show of hands. The proxy votes received for the meeting are set out below:
For | Against | Abstentions |
383,713,047 | 747,228 | 73,178 |
Text of Resolution
“That the transaction whereby a wholly-owned subsidiary of Shire Pharmaceuticals Group plc will merge with and into Transkaryotic Therapies, Inc. and pursuant to which Shire Pharmaceuticals Group plc will become the owner of record of all the outstanding capital stock in Transkaryotic Therapies, Inc. (the “Acquisition”) upon the terms and conditions of the Acquisition summarized in the Circular to Shareholders of the Company dated 27 June, 2005, with any amendments, modifications, variations or revisions thereto which are not of a material nature, be and is hereby approved and the directors of the Company (or any duly authorized committee thereof) be and are hereby authorized to do all such things and execute all such agreements and make such arrangements as may seem to them necessary, expedient or appropriate to give effect to the Acquisition.”
A copy of this resolution has been provided to the Financial Services Authority for publication through the document viewing facility.
For further information please contact: | ||||
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 | ||
Brian Piper (North America) | +1 484 595 8252 | |||
Media | Jessica Mann (Rest of the World) | +44 1256 894 280 | ||
Matthew Cabrey (North America) | +1 484 595 8248 |
Registered in England 2883758 Registered Office as above
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization, the impact of competitive products, including, but not limited to, the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire's ADHD franchise, government regulation and approval, including but not limited to Health Canada's suspension of ADDERALL XR® sales in Canada and the expected product approval dates of MTS (METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerative colitis) and NRP104 (ADHD), including its scheduling classification by the Drug Enforcement Agency in the United States, Shire’s ability to benefit from its acquisition of TKT, Shire's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year to December 31, 2004.
Registered in England 2883758 Registered Office as above